CEACAM5 and liver cancer: Levels of AFP-L3%, PIVKA-II, GALAD, ASAP, GALAD-C, GAAP, C-GALAD, C-GALAD II, CEA and CA19-9 in liver cancer (HCC and CCA) patients were significantly (p < 0.05) higher than those in patients with benign liver diseases (Table 2).